• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLDI alert in real time by email
    SC 13G 1 cldi.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Calidi Biotherapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

     

    (Title of Class of Securities)

     

    320703309

    (CUSIP Number)

     

    September 4, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 320703309   13G   Page 2 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Funicular Funds, LP

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2) The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

     

     

    CUSIP No. 320703309   13G   Page 3 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Cable Car Capital LLC (3)

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     
    ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

    (1) The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2)The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    (3)

    Cable Car Capital LLC, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital LLC, may each be deemed the beneficial owner of the shares held by Funicular Funds, LP.

     

     

     

    CUSIP No. 320703309   13G   Page 4 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Jacob Ma-Weaver (3)

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1) The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2)The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    (3)Cable Car Capital LLC, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital LLC, may each be deemed the beneficial owner of the shares held by Funicular Funds, LP.

     

     

     

    CUSIP No. 320703309   13G   Page 5 of 8 Pages

     

    Item 1.

     

    a.Name of Issuer

     

    Calidi Biotherapeutics, Inc.

     

    b.Address of Issuer’s Principal Executive Offices

     

    4475 Executive Drive, Suite 200, San Diego, CA 92121

     

    Item 2.

     

    (a)Name of Persons Filing

     

    Funicular Funds, LP

    Cable Car Capital LLC

    Jacob Ma-Weaver

     

    (b)Address of the Principal Office or, if none, residence

     

    601 California Street, #1151, San Francisco, CA 94108

     

    (c)Citizenship

     

    Funicular Funds, LP – Delaware

    Cable Car Capital LLC – California

    Jacob Ma-Weaver – United States

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value

     

    (e)CUSIP Number

     

    320703309

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 320703309   13G   Page 6 of 8 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    (b)Percent of class:

     

    Funicular Funds, LP – 9.99%

     

    Cable Car Capital LLC – 9.99%

     

    Jacob Ma-Weaver – 9.99%

     

    (c)Number of shares as to which the person has:

     

    i.Sole power to vote or to direct the vote

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    ii.Shared power to vote or to direct the vote

     

    Funicular Funds, LP – 0

     

    Cable Car Capital LLC – 0

     

    Jacob Ma-Weaver – 0

     

    iii.Sole power to dispose or to direct the disposition of

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    iv.Shared power to dispose or to direct the disposition of

     

    Funicular Funds, LP – 0

     

    Cable Car Capital LLC – 0

     

    Jacob Ma-Weaver – 0

     

    **See footnotes on cover pages which are incorporated by reference herein.

     

     

     

     

    CUSIP No. 320703309   13G   Page 7 of 8 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    Dated: September 11, 2024    
         
      FUNICULAR FUNDS, LP
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member of the General Partner
         
      CABLE CAR CAPITAL LLC
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member
       
      JACOB MA-WEAVER
       
      By: /s/ Jacob Ma-Weaver
        Jacob Ma-Weaver

     

     

     

     

    CUSIP No. 320703309   13G   Page 8 of 8 Pages

     

    Exhibit A

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: September 11, 2024    
         
      FUNICULAR FUNDS, LP
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member of the General Partner
         
      CABLE CAR CAPITAL LLC
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member
       
      JACOB MA-WEAVER
       
      By: /s/ Jacob Ma-Weaver
        Jacob Ma-Weaver

     

     

     

     

     

    Get the next $CLDI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDI

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

      SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL. The first candidate developed using RTNova is a vaccinia virus (virotherapy) that is engineered to be tumor selective and produced in an enveloped form that allows the virus to surv

      4/28/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

      11/22/23 7:15:52 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

      Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

      10/9/23 7:23:07 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLDI
    Financials

    Live finance-specific insights

    See more
    • Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

      Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

      3/31/25 4:10:00 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi: https://www.redchip.com/assets/access/cldi_accessGorilla Technology: https://www.redchip.com/assets/access/grrr_accessIn an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloombe

      10/18/24 8:45:00 AM ET
      $BOXL
      $CLDI
      $GRRR
      Other Consumer Services
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Poma Eric E

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:05:05 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Poma Eric E

      3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:01:32 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stewart Alan R. was granted 12,771 shares, increasing direct ownership by 79% to 28,976 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      1/3/25 5:27:37 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Calidi Biotherapeutics Inc.

      SCHEDULE 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      5/15/25 3:14:34 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/14/25 5:00:33 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Calidi Biotherapeutics Inc.

      10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/14/25 4:45:31 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

      SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      11/14/24 2:05:25 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

      SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      9/11/24 4:04:09 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care